Pancreatic Cancer Clinical Trials

Researchers are assessing different doses of TNG462 to give with daraxonrasib or zoldonrasib in people with advanced cancer. The people in this study have pancreatic cancer or non-small cell lung cancer (NSCLC) that spread beyond its original location. In addition, their cancers have a mutation (change) in the RAS gene and are missing a protein called MTAP.

The purpose of this study is to find the highest dose of the investigational drug AVA6000 that can be given safely in people with advanced solid tumors that are not responding to treatment. AVA6000 is very similar to a standard chemotherapy drug called doxorubicin. Like doxorubicin, AVA6000 works to slow or stop the growth of cancer cells by blocking an enzyme. Unlike doxorubicin, however, AVA6000 is a "prodrug," meaning it remains inactive until it reaches the site of the cancer. Because of the way AVA6000 works, it may be useful for treating cancer with fewer side effects than doxorubicin. AVA6000 is given intravenously (by vein).

Researchers want to find the best dose of ZL-1310 to use in people with advanced digestive tumors. The people in this study have gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) that spread and keeps growing after treatment. These tumors include NEC of the esophagus, stomach, pancreas, gallbladder, or colon/rectum.

Researchers are studying combining RMC-6236 with other anti-cancer drugs in people with advanced digestive cancers (pancreatic, colorectal cancer, and others). The people in this study have either:

In this study, researchers want to see how well a personalized vaccine works for people with pancreatic cancer. The people in this study have pancreatic cancer that can be taken out with surgery. The vaccine is called autogene cevumeran. It is an "mRNA vaccine," made in a way similar to the vaccines used to prevent COVID. It will be given in combination with a drug called atezolizumab and a chemotherapy treatment called mFOLFIRINOX.

Researchers want to see if giving NALIRIFOX chemotherapy with high-dose radiation therapy and capecitabine before surgery helps people with pancreatic cancer. The people in this study have pancreatic cancer that involves major blood vessels but has not spread to other organs. The study includes people with pancreatic cancer that may or may not be removable ("borderline resectable" or "locally advanced").

Researchers are comparing RMC-6236 with standard therapy in people with advanced pancreatic cancer. The people in this study have pancreatic cancer that has metastasized (spread) and keeps growing even after treatment.

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

The purpose of this study is to find the highest dose of the investigational immunotherapy drug TJ033721 that can be given safely in people with advanced cancers of the pancreas, esophagus, stomach, or junction between the esophagus and stomach. TJ033721 is an antibody that binds to Claudin 18.2, a protein expressed on some cancers cells, and to 4-1BB, a protein found on immune cells. TJ033721 may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. It is given intravenously (by vein).

The purpose of this study is to see if one year of treatment with olaparib is better than observation alone in patients who had pancreatic cancer surgically removed and who have mutations in the BRCA1, BRCA2 or PALB2 genes. Olaparib is a type of anticancer medication called a PARP inhibitor, which may slow down the process cancer cells use to repair their DNA. Cancer cells need to repair their DNA to survive and grow.